Background: Anecdotal evidence suggests that neurokinin 1 receptor antagonism reduces pruritus intensity in chronic pruritic conditions such as prurigo nodularis (PN).
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Chronic prurigo is a common end point of multiple pruritic conditions, defined by the presence of severe chronic pruritus and multiple localized or generalized pruriginous lesions. 1 Prurigo nodularis (PN), a subtype of chronic prurigo, is characterized by intensely pruritic, hyperkeratotic papulonodular lesions distributed along the upper and lower limbs and back. [1] [2] [3] These lesions dramatically impair patient quality of life. [4] [5] [6] PN primarily occurs in adults and is more common in women. 3, 4, 7, 8 PN occurs as a sequela to chronic pruritus associated with a number of conditions that result in chronic scratching. 2, 3, 9, 10 In the past decade, emerging research has increased understanding of the mechanisms underlying the itch process. 2, [11] [12] [13] Tachykinin substance P and its receptor neurokinin 1 (NK 1 R) play an important role in peripheral and central transmission of histamine-independent pruritus. 14, 15 Patients with PN have an increased number of substance Pepositive lesional skin nerve fibers, 2, 11, 16, 17 and serum substance P levels are increased in patients with chronic prurigo. 17 Comprehensive clinical trials in PN have not been undertaken; accordingly, there are currently no approved therapies for the treatment of pruritus associated with PN. Frequently used antipruritic therapies (emollients, topical corticosteroids, topical calcineurin inhibitors, systemic antihistamines, phototherapy, gabapentinoids, antidepressants, and immunosuppressants) 7 are often inadequate; some are associated with side effects that may limit their use. 7, 11, 18 There remains a significant unmet need for a safe antipruritic therapy that can effectively treat severe pruritus in PN and other conditions. The NK 1 R antagonist, aprepitant, which is US Food and Drug Administrationeapproved for prevention of chemotherapy-induced and postoperative nausea and vomiting, was shown to reduce pruritus intensity in a small (N = 20) uncontrolled study of patients with PN, 19 but its use beyond 3 days is not recommended on account of significant interactions with other drugs. 20, 21 Serlopitant is a small molecule, highly potent, selective NK 1 R antagonist that was developed for long-term oral administration. 22 Results from a phase 2, randomized double-blind, placebo-controlled, multicenter clinical trial of serlopitant, 5 mg daily, for pruritus in PN are reported.
METHODS
Trial design, oversight, and patient population
The study TCP-102 was conducted at 15 sites in Germany. Eligible patients were 18 to 80 years of age; had PN for more than 6 weeks and were refractory to previous antipruritic therapies (topical corticosteroids and/or oral antihistamines); in addition, they had generalized PN on both arms, both legs, and/or the trunk, and they had a visual analog scale (VAS) pruritus score of 7 cm or higher at screening. Exclusion criteria included the following: chronic pruritus due to conditions other than PN; use of antihistamines, steroids, other systemic antipruritic therapies, or immunosuppressants 1 to 2 weeks before the baseline visit; recent phototherapy; use of medications known to induce pruritus; serum creatinine level higher than 2.4 mg/dL; aspartate transaminase or alanine transaminase levels more than 2 times the upper limit of normal; untreated hyperthyroidism; recent treatment with strong cytochrome P450 3A4 inhibitors; and suicidal ideation with intent to act within the previous 12 months. Use of emollients and nonsedating antihistamines (as rescue medications) was permitted during the study.
The trial was conducted in accordance with the provisions of the Declaration of Helsinki, International Conference on Harmonization Good Clinical Practice guidelines, and applicable regulatory requirements. The study protocol and its amendments were approved by the appropriate institutional review boards or ethics committees. All patients provided written informed consent before participation in the trial.
Treatment and assessments
After a screening period of at least 4 weeks, patients were randomly assigned to receive serlopitant, 5 mg, or placebo orally once daily. A loading dose of 3 tablets was given on day 1, followed by 1
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In this study, the neurokinin 1 receptor antagonist serlopitant significantly reduced pruritus in patients with treatment-refractory prurigo nodularis, supporting the potential of neurokinin 1 receptor antagonism to disrupt itch signaling and reduce pruritus intensity. Serlopitant has potential as a therapeutic option for treatment of pruritus associated with prurigo nodularis. tablet daily at bedtime for 8 weeks. Patients were followed for a 2-week period after treatment. The primary efficacy end point was the average itch VAS pruritus intensity over the previous 24 hours, as determined by using a 10-cm scale recorded at study visits. Secondary efficacy end points included the worst itch VAS intensity over the previous 24 hours; average itch and worst itch numeric rating scale (NRS) pruritus scores over the previous 24 hours, as determined by an 11-point scale; verbal rating scale (VRS); physician-reported prurigo activity score; Investigator's Global Assessment (IGA) score; and use of rescue medication. Pruritus intensity was rated at study visits on the VAS and once daily with the NRS, VRS, and IGA in a patient diary (ItchApp eDiary 23 or paper version) from baseline to the end of the study. Baseline VAS scores were captured at the randomization visit. Patients who added their NRS scores to the electronic patient diary on day 1 were considered to have baseline NRS scores, although timing (before versus after taking the first dose of the assigned study drug) was not recorded. Subgroup analyses (ie, analyses by sex, atopic diathesis status, age, length of time with PN, and baseline average itch VAS score) were also performed. Post hoc analyses included a subgroup analysis for improvement in average itch VAS score based on history of atopic diathesis (eg, predisposition for developing hay fever, allergic rhinitis, bronchial asthma, or atopic dermatitis) and other factors, including an assessment of clinical improvement based on a 3-and 4-cm decrease in average itch VAS and a 4-point decrease in worst itch NRS as measures of response.
Safety end points were adverse events (AEs), treatment-emergent AEs (TEAEs), serious AEs, and clinical laboratory evaluations. AEs were classified by system organ class and preferred term according to the Medical Dictionary for Regulatory Activities, version 17.1. All analyses were performed in the intention-to-treat population (ie, all randomized patients who received at least 1 dose of study drug).
Randomization and masking
Patients were assigned to treatment groups by permuted block randomization (1:1) stratified by site with an interactive web-based response system (IWRS, Almac Clinical Services and Almac Clinical Technologies; Souderton, PA). Data were kept confidential and were accessible only to authorized persons until the time of unblinding. Placebo tablets were indistinguishable from serlopitant tablets.
The total target sample size of 140 patients was selected to achieve at least 90% power for the VAS change from baseline, assuming a treatment effect of at least 1.7 cm and a standard deviation of 3 or less.
Statistical analysis
The primary end point was analyzed by repeated measures analysis of covariance for average itch VAS score. The model used an unstructured covariance matrix and included change from baseline as the response variable and baseline average itch VAS score, visit, pooled site, treatment, and visit by treatment as the independent variables. Visit was included as a categoric variable. The estimated treatment difference (least square [LS] means) at weeks 2, 4, and 8 was summarized, and P values for these comparisons were provided. Missing data were not imputed before running the analysis. No multiplicity adjustment was prespecified for the analysis of weeks 4 and 8; therefore, the conservative Bonferroni adjustment (ie, an alpha level 2.5% for each time point) was retrospectively applied. The secondary efficacy end points, summarized with descriptive statistics, included estimates within the treatment group (eg, mean results for serlopitant). For select end points, estimates of the treatment effect, standard error (SE) (Wilson error for binary data and Wald error for continuous data), and statistical testing (t tests, Cochran-Mantel-Haenszel tests, or repeated measures) were performed without multiplicity control.
RESULTS
Of the 148 patients screened, 128 were randomized to serlopitant (n = 65) or placebo (n = 63); 1 patient in the serlopitant arm did not receive treatment and was not included in the analysis. In all, 23 The LS mean average itch VAS scores at weeks 2, 4, and 8 were 6.2 (SE, 0.29), 5.5 (SE, 0.33), and 4.4 (SE, 0.35), respectively, for serlopitant and 7.1 (SE, 0.29), 6.5 (SE, 0.35), and 6.1 (SE, 0.38), respectively, for placebo. At weeks 4 and 8, there was a statistically significant greater decrease from baseline in pruritus intensity (measured by average itch VAS score) with serlopitant versus with placebo, with an LS mean difference (improvement in serlopitant minus improvement in placebo) of À1.0 (95% confidence interval [CI], À1.8 to À0.1) (P = .025) at week 4 and À1.7 (95% CI, À2.6 to À0.7) (P \ .001) at week 8. Reductions from baseline in pruritus intensity were observed as early as week 2 with serlopitant versus with placebo, with an LS mean difference of À0.9 (95% CI, À1.5 to À0.2) (P = .011). The mean percentage changes from baseline in mean average itch VAS score at weeks 2, 4, and 8 were À22.8%, À31.2%, and À48.3%, respectively, in the serlopitant group and À11.2%, À17.2%, and À26.3%, respectively, in the placebo group (Fig 1, A) .
Subgroup analyses for change from baseline in average itch VAS score at week 8 demonstrated consistent reduction in itch score across the subgroups except for patients who had a baseline average itch VAS score greater than the median of 8.1 at week 8 (Fig 1, B) . In patients with atopic diathesis, the LS mean difference between serlopitant and placebo for change from baseline in average itch VAS score at week 8 was À2.20 (95% CI, À3.45 to À0.95). The percentages of patients who were 4-cm responders for average itch VAS score at week 8 were 54.4% for serlopitant and 25.0% for placebo (P = .002); a similar trend was observed for 3-cm responder analysis (63.2% for serlopitant and 33.3% for placebo [P = .0013]).
Serlopitant provided greater reduction in pruritus across secondary measures than placebo (Fig 2) . As with the average itch VAS scores, there was a significantly greater improvement in worst itch VAS score with serlopitant versus with placebo at week 8, with a mean difference in change from baseline of À1.6 (95% CI, À2.6 to À0.6) (P = .002). LS mean (SE) average itch NRS scores at weeks 2, 4, and 8 were 5.5 (SE, 0.26), 4.9 (SE, 0.29), and 4.1 (SE, 0.31), respectively, for serlopitant and 6.3 (SE, 0.27), 5.9 (SE, 0.30), and 5.4 (SE, 0.32), respectively, for placebo. There was a significantly greater decrease from baseline in average itch NRS scores in the serlopitant group at weeks 2, 4, and 8 compared with in the placebo group, with a mean difference of À0.9 (95% CI, À1.6 to À0.2) (P = .009) at week 2; À1.2 (95% CI, À1.9 to À0.4) (P = .004) at week 4; and À1.4 (95% CI, À2.3 to À0.4) (P = .007) at week 8 (Fig 2) . The mean percentage changes from baseline in worst itch NRS score at weeks 2, 4, and 8 were À19.4%, À25.7%, and À37.2%, respectively, in the serlopitant group and À14.8%, À18.6%, and À26.4%, respectively, in the placebo group. At week 8, the percentages of patients who were 4-point responders for worst itch NRS score were 46.5% for serlopitant and 25.6% for placebo (P = .045). Greater improvements in pruritus for serlopitantversus placebo-treated patients were reported on the VRS (percentage of patients reporting no or mild pruritus at week 8: serlopitant 54.4% vs placebo 28.9% [P = .006]) and improvements in lesions on the IGA at week 8 (66.7% with serlopitant vs 40.4% with placebo [P = .025]). Both groups showed improvement on the prurigo activity score, but the serlopitant group appeared to show a proportionately greater level of improvement in percentage of healed excoriations of PN lesions from baseline to week 8 (for patients with #25% of lesions with excoriations at week 8, the percentages were 33.3% with serlopitant and 23.4% with placebo [P = .093]), though the differences were not significant. During the study, rescue medication was used by a lower percentage of serlopitant-treated (12.5%) than placebo-treated (19.0%) patients.
TEAEs were reported in 46 serlopitant-treated patients (71.9%) and 39 placebo-treated patients (61.9%). The most frequently reported TEAEs in the serlopitant group were nasopharyngitis (17.2%), diarrhea (10.9%), and fatigue (9.4%) ( Table II) . Most TEAEs were mild or moderate, and no deaths were reported. Severe TEAEs included atopic dermatitis, cough, depression, diarrhea, dizziness, fatigue, pruritus, and vertigo in the serlopitant group and pruritus, insomnia, and respiratory failure in the placebo group. TEAEs led to discontinuation in 9 patients (3 treated with serlopitant and 6 treated with placebo). Serious AEs were reported in 3 patients in the serlopitant group (vertigo and dizziness, depression, and actinic elastosis in 1 patient each) and 2 patients in the placebo group (bradycardia, syncope, and respiratory failure in 1 patient and neurodermatitis in 1 patient). There were no clinically relevant differences in laboratory parameters, electrocardiogram, or vital signs observed between treatment groups.
DISCUSSION
There is no approved therapy for pruritus in PN, and patients often experience pruritus that is refractory to commonly used treatments. 7, 11, 18, 24 This trial investigated the safety, tolerability, and efficacy of the NK 1 R antagonist serlopitant in the treatment of pruritus in PN.
In a prior proof-of-concept study, serlopitant was well tolerated and demonstrated superior reduction in chronic pruritus compared with placebo. 25 In the current study, serlopitant, 5 mg, was superior to placebo at weeks 4 and 8 for the reduction of pruritus, as measured by average itch VAS score. The minimal clinically important difference for measuring benefit in pruritus as rated on the VAS is a decrease of 3 cm. 26 Here, at week 8, a significantly greater proportion of patients in the serlopitant group than in the placebo group were 3-cm and 4-cm responders on the average itch VAS. Further, reductions in pruritus were observed as early as 2 weeks following serlopitant administration.
Subgroup analyses for change from baseline in average itch VAS score at week 8 confirmed the findings of the overall study population, except for patients with a baseline average itch VAS score greater than the median of 8.1. The lack of treatment effect observed in this subgroup may have been driven by an increased early withdrawal rate in the placebo group (7 patients) compared with in the serlopitant group (1 patient). Specifically, the increased rate of withdrawal of patients in the placebo group, which had the highest baseline average itch VAS scores, may have reduced the difference in average itch VAS scores between treatment groups. Notably, in patients with atopic diathesis, there was a numerically greater treatment effect at week 8 with serlopitant versus with placebo than was observed in the full study population. This is consistent with findings from a previously published case series of patients with atopic diathesis, in which treatment with aprepitant resulted in significant reductions in pruritus (P \.01). 19 Results from a of trial of tradipitant used to treat chronic atopic dermatitis showed significant improvement in worst itch VAS (secondary end point) but not in average itch VAS (primary end point) compared with placebo (NCT02651714). 27 However, in a trial of serlopitant in patients with pruritus and a history of atopic dermatitis, the primary and secondary end points did not reach statistical significance (NCT02975206), 28 indicating that further exploration of the antiinflammatory effects of NK 1 R antagonists is needed.
The reduction in pruritus by serlopitant was demonstrated by multiple secondary pruritus measures, including the NRS and VRS. Healing of PN lesions is expected to require several months or longer, 1 necessitating a longer duration of treatment than in this 8-week trial. Accordingly, the course of PN as observed here did not improve significantly. Serlopitant-treated patients were less likely to use rescue medication than placebo-treated patients were. Overall, serlopitant was well tolerated among patients with treatment-refractory PN.
The primary limitation of this study is the 8-week treatment duration, which was not sufficient to determine whether the reductions in pruritus will lead to substantial, clinically relevant resolution of PN lesions. In addition, we could not compare the effects of serlopitant observed in this study with those of other treatments for PN, as randomized, controlled trials have not been performed. In an open-label, prospective study of 12 patients who received the antihistamines fexofenadine (240 mg twice daily) and montelukast (10 mg once daily) for 4 weeks, 75% of patients reported some improvement in pruritus and number of lesions; however, most of these improvements were deemed only slight. 29 An open-label trial of the opioid antagonist naltrexone (50 mg daily) in 17 patients with PN demonstrated a high antipruritic effect in 53% of patients. 30 A small (N = 4) case series of use of gabapentin (900 mg once daily) in patients with PN reported reductions in pruritus after about 3 to 4 months of treatment. 31 In an open-label, prospective study of 30 patients with PN, 76% had a response to pregabalin (75 mg once daily) after 3 months, defined as disappearance of pruritus and reduction of nodules. 32 Nevertheless, without randomized, controlled trials, the efficacy of these interventions can be considered only anecdotal.
In conclusion, serlopitant has potential as a therapeutic option for the treatment of pruritus in patients with treatment-refractory PN. The results from this randomized, controlled study support its continued evaluation in this patient population.
